ECHELONAesthetics Institute Inc
Emerging / Investigational

Retatrutide research.

An educational introduction to a triple hormone receptor agonist being studied in clinical trials.

Emerging / Investigational — Not FDA-approved

What is being studied?

Retatrutide activates GIP, GLP-1 and glucagon receptors. Lilly is studying this investigational molecule in clinical trials for obesity, type 2 diabetes and related conditions.

Research is not availability.

Retatrutide has not been approved by the FDA. Lilly states that it is available only to participants in its clinical trials. This page provides research education and does not offer treatment, ordering or prescribing.

Read the research article